In yesterday’s Wall Street session, Aclaris Therapeutics Inc (NASDAQ:ACRS) shares traded at $4.59, up 46.18% from the previous session.
ACRS stock price is now 187.31% away from the 50-day moving average and 251.72% away from the 200-day moving average. The market capitalization of the company currently stands at $327.86M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target enhanced from $2 to $7, Leerink Partners Upgraded its rating from Market Perform to Outperform for Aclaris Therapeutics Inc (NASDAQ: ACRS). On November 20, 2024, Jefferies Upgraded its previous ‘Hold’ rating to ‘Buy’ on the stock increasing its target price from $2 to quote $7, while ‘BTIG Research’ rates the stock as ‘Buy’
In other news, Leonard Braden Michael, 10% Owner bought 206,025 shares of the company’s stock on Aug 05 ’24. The stock was bought for $256,357 at an average price of $1.24. Upon completion of the transaction, the 10% Owner now directly owns 14,250,000 shares in the company, valued at $65.41 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 02 ’24, 10% Owner Leonard Braden Michael bought 167,544 shares of the business’s stock. A total of $216,400 was incurred on buying the stock at an average price of $1.29. This leaves the insider owning 14,043,975 shares of the company worth $64.46 million. A total of 4.01% of the company’s stock is owned by insiders.
During the past 12 months, Aclaris Therapeutics Inc has had a low of $0.77 and a high of $3.54. As of last week, the company has a debt-to-equity ratio of 0.02, a current ratio of 7.03, and a quick ratio of 7.03. The fifty day moving average price for ACRS is $1.5292 and a two-hundred day moving average price translates $1.2878 for the stock.
The latest earnings results from Aclaris Therapeutics Inc (NASDAQ: ACRS) was released for 2024-09-30. The net profit margin was -136.65% and return on equity was -25.83% for ACRS. The company reported revenue of $4.35 million for the quarter, compared to $9.28 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -53.18 percent.
